Single‐syringe Administration of Diluted Adenosine

Comparison between the double‐syringe and the single‐syringe techniques of adenosine administration for terminating supraventricular tachycardia: A pilot, randomized controlled trial

“…This is consistent with the epidemiology of SVT (especially AVNRT) in the general population, which was reported as being more common in women 1 . Patient age in our study was similar to that in studies by McDowell et al 10 and Goyal et al, 13 in which the mean age was 54–58 years. However, a study by Choi et al 11 reported a lower average age of SVT patients in Korea (mean age of 48 years).…”

“…This result was consistent with a nonblind, randomized prospective study conducted by Choi et al, 11 which found a higher successful termination rate using SST method (SST 85.7% vs. DST 80%, p = .390). The findings were also in line with an observational study by McDowell et al, 10 which demonstrated that SST resulted in a higher success rate after the first dose (6 mg) than DST (73.1% vs. 40%, p = .017). Furthermore, the total average dosage of adenosine required for SVT termination in the SST group was slightly lower than that of the DST group (7.6 vs. 8.6 mg, p = .928).…”

“…A more convenient single syringe technique (SST), has thus been proposed, in which a bolus of adenosine is mixed with NSS up to 15–20 ml and administered intravenously. 10 In a previous nonblind randomized prospective study, this method resulted in a higher success rate than the DST (85.7 vs. 80%), but the difference was not statistically significant. 11 Another observational study found that the SST resulted in a similar conversion success rate to that of the DST.…”

“…We did not observe any adverse events in either group, which was consistent with both studies mentioned above. 10 , 11 However, adenosine may theoretically cause side effects such as transient AV block, flushing, chest pain, hypotension, dyspnea, atrial fibrillation (AF), premature ventricular tachycardias (PVCs) or ventricular tachycardia (VT), bronchospasm (rare), or coronary steal. 16 , 17 , 18 , 19 We excluded patients with concomitant acute asthmatic attack, and patients with history of adenosine allergy to minimize the risk of any possible adverse events mentioned above.…”

“…11 Another observational study found that the SST resulted in a similar conversion success rate to that of the DST. 10 However, to the best of our knowledge, no randomized controlled trial (RCT) with a blind protocol has been conducted to confirm this result. We thus conducted this multicenter RCT to evaluate the non‐inferiority of the SST compared with the DST in terminating stable SVT.…”